SAVE RARE TREATMENTS TASK FORCE

Lobbying client · District of Columbia · filed 2025 to 2026

Dedicated to restoring the spirit of R&D incentives in the Orphan Drug Act.

$340,000 Reported spend

7 Filings counted

1 Outside firm hired

0 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page comes from one LDA client record (58112), filed by the registrant listed below.

Who filed for this client 1

LEAVITT PARTNERS, LLC $340,000 Outside firm · 7 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Reported by year 2 years

2026 $130,000 3 filings
2025 $210,000 4 filings

Issues lobbied 1

Health Issues 7

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 7
SENATE 7

Recent filings 7 total

Q3 report

LEAVITT PARTNERS, LLC

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $40,000 income · posted Oct 20, 2026

View → Q2 report

LEAVITT PARTNERS, LLC

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $40,000 income · posted Jul 15, 2026

View → Q1 report

LEAVITT PARTNERS, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026

View → Q4 report

LEAVITT PARTNERS, LLC

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $40,000 income · posted Jan 9, 2026

View → Q3 report

LEAVITT PARTNERS, LLC

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2025

View → Q2 report

LEAVITT PARTNERS, LLC

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 15, 2025

View → Q1 report

LEAVITT PARTNERS, LLC

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $40,000 income · posted Apr 22, 2025

View →

Affiliated organisations 2

AGIOS PHARMACEUTICALS United States of America named on 1 filing
ALKERMES, INC. United States of America named on 1 filing

Section 6 of the LD-2: organisations that contribute to or take part in this client's lobbying.

Keep going

Filings through October 20, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.